251 related articles for article (PubMed ID: 36590752)
1. Prognostic Value of Lymphocyte-to-Monocyte Ratio (LMR) in Cancer Patients Undergoing Immune Checkpoint Inhibitors.
Wan L; Wu C; Luo S; Xie X
Dis Markers; 2022; 2022():3610038. PubMed ID: 36590752
[TBL] [Abstract][Full Text] [Related]
2. Prognostic value of lymphocyte-to-monocyte ratio in gastric cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Mei P; Feng W; Zhan Y; Guo X
Front Immunol; 2023; 14():1321584. PubMed ID: 38090560
[TBL] [Abstract][Full Text] [Related]
3. The relationship between NLR/PLR/LMR levels and survival prognosis in patients with non-small cell lung carcinoma treated with immune checkpoint inhibitors.
Liu N; Mao J; Tao P; Chi H; Jia W; Dong C
Medicine (Baltimore); 2022 Jan; 101(3):e28617. PubMed ID: 35060536
[TBL] [Abstract][Full Text] [Related]
4. Effects of glucocorticoid use on survival of advanced non-small-cell lung cancer patients treated with immune checkpoint inhibitors.
Li N; Zheng X; Gan J; Zhuo T; Li X; Yang C; Wu Y; Qin S
Chin Med J (Engl); 2023 Nov; 136(21):2562-2572. PubMed ID: 37925595
[TBL] [Abstract][Full Text] [Related]
5. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
6. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2021 Apr; 4(4):CD013257. PubMed ID: 33930176
[TBL] [Abstract][Full Text] [Related]
7. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis.
Chen H; Han KD; He ZJ; Huang YS
Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149
[TBL] [Abstract][Full Text] [Related]
8. Predictive value of neutrophil-lymphocyte ratio and platelet-lymphocyte ratio in non-small cell lung cancer patients treated with immune checkpoint inhibitors: A meta-analysis.
Zhang N; Jiang J; Tang S; Sun G
Int Immunopharmacol; 2020 Aug; 85():106677. PubMed ID: 32531712
[TBL] [Abstract][Full Text] [Related]
9. The impact of antibiotic use on clinical features and survival outcomes of cancer patients treated with immune checkpoint inhibitors.
Zhou J; Huang G; Wong WC; Hu DH; Zhu JW; Li R; Zhou H
Front Immunol; 2022; 13():968729. PubMed ID: 35967438
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis.
Shen K; Cui J; Wei Y; Chen X; Liu G; Gao X; Li W; Lu H; Zhan P; Lv T; Lin D
J Thorac Dis; 2018 Dec; 10(12):6636-6652. PubMed ID: 30746209
[TBL] [Abstract][Full Text] [Related]
11. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
[TBL] [Abstract][Full Text] [Related]
12. Patients with melanoma treated with immune checkpoint inhibitors who had non-thyroid endocrine and skin immune-related adverse events have better prognosis: A systematic review and meta-analysis.
Sun Q; Sun H; Wu N; Hu Y; Zhang F; Cong X
Front Oncol; 2022; 12():976224. PubMed ID: 36185176
[TBL] [Abstract][Full Text] [Related]
13. Association of Lymphocyte-to-Monocyte Ratio With Survival in Advanced Gastric Cancer Patients Treated With Immune Checkpoint Inhibitor.
Chen Y; Zhang C; Peng Z; Qi C; Gong J; Zhang X; Li J; Shen L
Front Oncol; 2021; 11():589022. PubMed ID: 34141607
[TBL] [Abstract][Full Text] [Related]
14. Impact of probiotics use on clinical outcomes of immune checkpoint inhibitors therapy in cancer patients.
Wan L; Wu C; Wu Q; Luo S; Liu J; Xie X
Cancer Med; 2023 Jan; 12(2):1841-1849. PubMed ID: 35770869
[TBL] [Abstract][Full Text] [Related]
15. Prognostic impact of circulating monocytes and lymphocyte-to-monocyte ratio on previously untreated metastatic non-small cell lung cancer patients receiving platinum-based doublet.
Lin GN; Peng JW; Xiao JJ; Liu DY; Xia ZJ
Med Oncol; 2014 Jul; 31(7):70. PubMed ID: 24927957
[TBL] [Abstract][Full Text] [Related]
16. Prognostic Value of Pretreatment Lymphocyte-to-Monocyte Ratio in Non-Small Cell Lung Cancer: A Meta-Analysis.
Wang Y; Huang D; Xu WY; Wang YW; Che GW
Oncol Res Treat; 2019; 42(10):523-531. PubMed ID: 31319409
[TBL] [Abstract][Full Text] [Related]
17. Multisystem Immune-Related Adverse Events Associated With Immune Checkpoint Inhibitors for Treatment of Non-Small Cell Lung Cancer.
Shankar B; Zhang J; Naqash AR; Forde PM; Feliciano JL; Marrone KA; Ettinger DS; Hann CL; Brahmer JR; Ricciuti B; Owen D; Toi Y; Walker P; Otterson GA; Patel SH; Sugawara S; Naidoo J
JAMA Oncol; 2020 Dec; 6(12):1952-1956. PubMed ID: 33119034
[TBL] [Abstract][Full Text] [Related]
18. Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer.
Sekine K; Kanda S; Goto Y; Horinouchi H; Fujiwara Y; Yamamoto N; Motoi N; Ohe Y
Lung Cancer; 2018 Oct; 124():179-188. PubMed ID: 30268458
[TBL] [Abstract][Full Text] [Related]
19. The relationship between blood-based tumor mutation burden level and efficacy of PD-1/PD-L1 inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis.
Ba H; Liu L; Peng Q; Chen J; Zhu YD
BMC Cancer; 2021 Nov; 21(1):1220. PubMed ID: 34774004
[TBL] [Abstract][Full Text] [Related]
20. The impact of antibiotics on efficacy of immune checkpoint inhibitors in malignancies: A study based on 44 cohorts.
Wu Q; Liu J; Wu S; Xie X
Int Immunopharmacol; 2021 Mar; 92():107303. PubMed ID: 33465728
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
